


# Accepted Manuscript

A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in *Pichia pastoris*

Fabrice Cerini, Hubert Gaertner, Knut Madden, Ilya Tolstorukov, Scott Brown, Bram Laukens, Nico Callewaert, Jay C. Harner, Anna M. Oommen, John T. Harms, Anthony R. Sump, Robert C. Sealock, Dustin J. Peterson, Scott K. Johnson, Stephan B. Abramson, Michael Meagher, Robin Offord, Oliver Hartley



PII: S1046-5928(15)30090-5

DOI: [10.1016/j.pep.2015.10.011](https://doi.org/10.1016/j.pep.2015.10.011)

Reference: YPREP 4815

To appear in: *Protein Expression and Purification*

Received Date: 26 June 2015

Revised Date: 22 September 2015

Accepted Date: 19 October 2015

Please cite this article as: F. Cerini, H. Gaertner, K. Madden, I. Tolstorukov, S. Brown, B. Laukens, N. Callewaert, J.C. Harner, A.M. Oommen, J.T. Harms, A.R. Sump, R.C. Sealock, D.J. Peterson, S.K. Johnson, S.B. Abramson, M. Meagher, R. Offord, O. Hartley, A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in *Pichia pastoris*, *Protein Expression and Purification* (2015), doi: 10.1016/j.pep.2015.10.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**A scalable low-cost cGMP process for clinical grade  
production of the HIV inhibitor 5P12-RANTES in *Pichia*  
*pastoris***

Fabrice Cerini<sup>1</sup>, Hubert Gaertner<sup>1</sup>, Knut Madden<sup>2</sup>, Ilya Tolstorukov<sup>2,3</sup>, Scott Brown<sup>4</sup>,  
Bram Laukens<sup>5,6</sup>, Nico Callewaert<sup>5,6</sup>, Jay C. Harner<sup>7</sup>, Anna M. Oommen<sup>7</sup>, John T.  
Harms<sup>7</sup>, Anthony R. Sump<sup>7</sup>, Robert C. Sealock<sup>7</sup>, Dustin J. Peterson<sup>7</sup>, Scott K.  
Johnson<sup>7</sup>, Stephan B. Abramson<sup>8</sup>, Michael Meagher<sup>7\*</sup>, Robin Offord<sup>9</sup> and Oliver  
Hartley<sup>1,9</sup>

<sup>1</sup>Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

<sup>2</sup>BioGrammatics Inc., Carlsbad, California 92011, USA.

<sup>3</sup>Keck Graduate Institute, Claremont, California, USA

<sup>4</sup>Biologics Process Development, Inc., Poway, California 92064, USA

<sup>5</sup>Department of Medical Protein Research, VIB-UGent, Ghent, Belgium.

<sup>6</sup>Department of Biochemistry and Microbiology, Laboratory for Protein Biochemistry and Biomolecular Engineering, Ghent University, Ghent, Belgium.

<sup>7</sup>University of Nebraska-Lincoln Biological Process Development Facility, College of Engineering, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.

<sup>8</sup>LifeSci Partners, LLC, Vancouver, Washington 98686-2811, USA.

<sup>9</sup>The Mintaka Foundation for Medical Research, Geneva, Switzerland.

\*Present address: Department of Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis TN, 38105, USA.

**Corresponding author:** [oliver.hartley@unige.ch](mailto:oliver.hartley@unige.ch)

**Keywords:** *Pichia*; yeast; process development; chemokine; HIV; microbicide; CCR5; 5P12-RANTES; biopharmaceutical; GMP

Download English Version:

<https://daneshyari.com/en/article/8359822>

Download Persian Version:

<https://daneshyari.com/article/8359822>

[Daneshyari.com](https://daneshyari.com)